Hybrid Ganciclovir/Valacyclovir Prophylaxis Reduces CMV Reactivation in High-Risk Allogeneic Stem Cell Transplant Recipients.

Similarly, despite the higher probability rates of DFS and GFRS observed in the hybrid group than the preemptive group, these differences did not reach statistical significance (61.38% (95% CI: 42.91-75.46) vs. 56.1% (95% CI: 40.54-69.07), P= 0.55 for DFS and 33.83% (95% CI: 17.66-50.79) vs. 13.28% (95% CI: 5.09-25.44), P= 0.10 for GRFS).

also in 111,027 other papers